Patents by Inventor Alan Northrup

Alan Northrup has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Pyrazolo[1,5-A]pyrimidines as mark inhibitors
    Patent number: 8946237
    Abstract: The invention encompasses pyrazolo[1,5-a]pyrimidine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: January 11, 2011
    Date of Patent: February 3, 2015
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Jongwon Lim, Brandon M. Taoka, Sandra Lee, Alan Northrup, Michael D. Altman, David L. Sloman, Matthew G. Stanton, Njamkou Noucti
  • Imidazo[1,2-a]pyridines and imidazo[1,2-b]pyridazines as mark inhibitors
    Patent number: 8592425
    Abstract: The invention encompasses imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
    Type: Grant
    Filed: January 12, 2010
    Date of Patent: November 26, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Michael D. Altman, Mark T. Bilodeau, Jongwon Lim, Alan Northrup, Matthew G. Stanton, Brandon M. Taoka
  • PYRAZOLO[1,5-A]PYRIMIDINES AS MARK INHIBITORS
    Publication number: 20130210838
    Abstract: The invention encompasses pyrazolo[1,5-a]pyrimidine derivatives which selectively inhibit microtubule affinity regulating kinase (MARK) and are therefore useful for the treatment or prevention of Alzheimer's disease. Pharmaceutical compositions and methods of use are also included.
    Type: Application
    Filed: January 11, 2011
    Publication date: August 15, 2013
    Inventors: Jongwon Lim, Brandon M. Taoka, Sandra Lee, Alan Northrup, Michael D. Altman, David L. Sloman, Matthew G. Stanton, Njamkou Noucti
  • Inhibitors of janus kinases
    Patent number: 8349865
    Abstract: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
    Type: Grant
    Filed: September 8, 2008
    Date of Patent: January 8, 2013
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tony Siu, Jonathan Young, Michael Altman, Alan Northrup, Matthew Katcher, Ellalahewage Sathyajith Kumarasinghe, Ekaterina Kozina, Scott Peterson, Matthew Childers
  • Inhibitors of janus kinases and/or 3-phosphoinositide-dependent protein kinase-1
    Patent number: 8329722
    Abstract: The instant invention provides for compounds that inhibit JAK2 tyrosine kinase and/or PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting JAK2 tyrosine kinase activity and/or PDK1 kinase inhibitory activity by administering the compound to a patient in need of treatment or prevention of myeloproliferative disorders or cancer.
    Type: Grant
    Filed: March 10, 2008
    Date of Patent: December 11, 2012
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Tony Siu, Jonathan Young, Michael Altman, Alan Northrup, Ekaterina Kozina, Christopher Dinsmore, David J. Guerin, Kevin A. Keenan, Joon O. Jung, Solomon Kattar, Rachel N. MacCoss
  • INHIBITORS OF JANUS KINASES
    Publication number: 20100197634
    Abstract: The instant invention provides for compounds that inhibit the four known mammalian JAK kinases (JAK1, JAK2, JAK3 and TYK2) and PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting the activity of JAK1, JAK2, JAK3 TYK2 and PDK1 by administering the compound to a patient in need of treatment for myeloproliferative disorders or cancer.
    Type: Application
    Filed: September 8, 2008
    Publication date: August 5, 2010
    Inventors: Tony Siu, Jonathan Young, Michael Altman, Alan Northrup, Matthew Katcher, Ellalahewage Sathyajith Kumarasinghe, Ekaterina Kozina, Scott Peterson, Matthew Childers
  • INHIBITORS OF JANUS KINASES AND/OR 3-PHOSPHOINOSITIDE-DEPENDENT PROTEIN KINASE-1
    Publication number: 20100160309
    Abstract: The instant invention provides for compounds that inhibit JAK2 tyrosine kinase and/or PDK1. The invention also provides for compositions comprising such inhibitory compounds and methods of inhibiting JAK2 tyrosine kinase activity and/or PDK1 kinase inhibitory activity by administering the compound to a patient in need of treatment or prevention of myeloproliferative disorders or cancer.
    Type: Application
    Filed: March 10, 2008
    Publication date: June 24, 2010
    Inventors: Tony Siu, Jonathan Young, Micheal Altman, Alan Northrup, Ekaterina Kozina, Christopher Dinsmore, David J. Guerin, Kevin A. Keenan, Joon O. Jung, Solomon Kattar, Rachel N. MacCoss
  • Direct, enantioselective aldol coupling of aldehydes using chiral organic catalysts
    Publication number: 20050197498
    Abstract: Nonmetallic, chiral organic catalysts are used to catalyze an enantioselective aldol coupling reaction between aldehyde substrates. The reaction may be carried out with a single enolizable aldehyde, resulting in dimerization to give a ?-hydroxy aldehyde, or trimerization to give a dihydroxy tetrahydropyran. The reaction may also conducted with an enolizable aldehyde and a second aldehyde, which may or may not be enolizable, so that the coupling is a cross-aldol reaction in which the ?-carbon of the enolizable aldehyde adds to the carbonyl carbon of the second aldehyde in an enantioselective fashion. Reaction systems composed of at least one enolizable aldehyde, an optional additional aldehyde, and the nonmetallic chiral organic catalyst are also provided, as are methods of implementing the enantioselective aldol reaction in the synthesis of sugars.
    Type: Application
    Filed: April 21, 2005
    Publication date: September 8, 2005
    Applicant: California Institute of Technology
    Inventors: David MacMillan, Alan Northrup